✦HEALTH · 30% off Purgo Labs✦
Beginner Guide6 Families · 30+ Compounds

Research Peptide Families Explained

A structured overview of the six major research peptide families — their receptor targets, mechanisms of action, key compounds, and a goal-based decision matrix to guide your research focus.

6
Peptide Families
30+
Compounds Covered
3
FDA-Approved Compounds
8+
Receptor Systems

Why Peptide Families Matter

Research peptides are not a monolithic category. They span six distinct biochemical families, each acting on different receptor systems, producing different downstream effects, and serving different research applications. Understanding which family a compound belongs to is the first step in designing a coherent research protocol — before considering individual compounds, dosing, or stacking strategies.

The six families covered in this guide are: GHRH analogues (pituitary GH axis stimulation), GHRP peptides (ghrelin receptor-mediated GH release), GLP-1 receptor agonists (metabolic and glycemic regulation), recovery and repair peptides (tissue regeneration), longevity peptides (cellular aging and mitochondrial function), and cognitive/nootropic peptides (neuroprotection and CNS modulation).

Research context: All compounds discussed on this page are research-grade peptides intended for laboratory and preclinical research purposes only. They are not approved for human use (except where FDA approval is noted) and should not be interpreted as medical advice.

The Six Research Peptide Families

Each family card summarizes the receptor target, mechanism, key compounds, and primary research applications. Click the hub link to access the full family reference guide.

1. GHRH Analogues

Most Studied

Growth Hormone Releasing Hormone

Receptor Target
GHRH-R (pituitary)
Half-Life Range
Minutes–days (varies by analogue)
FDA Approval
Tesamorelin (HIV lipodystrophy)
Mechanism
Stimulate pituitary somatotrophs to synthesize and release GH in a pulsatile pattern
Key Compounds
SermorelinCJC-1295Tesamorelin
Primary Research Goals
Lean mass gainsFat loss (visceral)Recovery accelerationAnti-aging
Best For
Researchers seeking physiological GH restoration with preserved pulsatility

2. GHRP Peptides

Early Trials

Growth Hormone Releasing Peptides

Receptor Target
GHS-R1a (ghrelin receptor)
Half-Life Range
15 min–2 hours
FDA Approval
None
Mechanism
Mimic ghrelin to stimulate GH release via a separate receptor pathway; synergistic with GHRH
Key Compounds
IpamorelinGHRP-2GHRP-6
Primary Research Goals
GH pulse amplificationMuscle growthBody compositionSleep quality
Best For
Researchers studying GH release through the ghrelin receptor

3. GLP-1 / Metabolic Peptides

FDA Approved

Glucagon-Like Peptide-1 Receptor Agonists

Receptor Target
GLP-1R (pancreas, hypothalamus, gut)
Half-Life Range
Days–weeks
FDA Approval
Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound)
Mechanism
Enhance glucose-dependent insulin secretion, slow gastric emptying, reduce appetite via CNS
Key Compounds
SemaglutideTirzepatideRetatrutide
Primary Research Goals
Weight lossGlycemic controlCardiovascular risk reductionMetabolic health
Best For
Researchers studying metabolic syndrome, obesity, and type 2 diabetes mechanisms

4. Recovery & Repair Peptides

Most Popular

Tissue Regeneration & Healing

Receptor Target
Multiple (growth factor receptors, integrin pathways)
Half-Life Range
Hours
FDA Approval
None
Mechanism
Upregulate growth factor expression, promote angiogenesis, accelerate extracellular matrix remodeling
Key Compounds
BPC-157TB-500Wolverine Blend
Primary Research Goals
Injury recoveryTendon/ligament repairGut healingAnti-inflammatory
Best For
Researchers studying musculoskeletal repair, wound healing, and tissue regeneration

5. Longevity & Anti-Aging Peptides

Emerging Research

Cellular Health & Senescence

Receptor Target
Mitochondrial targets, telomerase, epigenetic regulators
Half-Life Range
Variable
FDA Approval
None
Mechanism
Modulate mitochondrial function, telomere length, NAD+ metabolism, and cellular senescence pathways
Key Compounds
EpithalonMOTS-cSS-31NAD+GHK-Cu
Primary Research Goals
Cellular longevityMitochondrial functionTelomere maintenanceOxidative stress reduction
Best For
Researchers studying aging biology, mitochondrial dysfunction, and cellular senescence

6. Cognitive & Nootropic Peptides

Niche Research

Neuroprotection & CNS Enhancement

Receptor Target
Sigma-1, dopamine, BDNF pathways
Half-Life Range
Minutes–hours
FDA Approval
Selank/Semax (Russia only)
Mechanism
Modulate neurotransmitter systems, promote neuroplasticity, reduce neuroinflammation
Key Compounds
SelankSemaxDihexa
Primary Research Goals
Cognitive enhancementAnxiety reductionNeuroprotectionBDNF upregulation
Best For
Researchers studying neuroplasticity, anxiety, and cognitive function

Family Comparison at a Glance

A side-by-side reference comparing the six families across the most clinically relevant dimensions.

FamilyReceptorGH EffectCortisolFDA ApprovedHuman evidence
GHRH AnaloguesGHRH-RHigh (pulsatile)NoneTesamorelinApproved drug (tesamorelin)
GHRP PeptidesGHS-R1aHighMinimal–ModerateNoneEarly trials
GLP-1 AgonistsGLP-1RNoneNoneSema, TirzLarge Phase 3 trials
Recovery PeptidesMultiple (GF)NoneNoneNoneAnimal; tiny human reports
Longevity PeptidesMitochondrialNoneNoneNoneMostly animal
Cognitive PeptidesSigma-1, DANoneNoneNone (Russia)Small Russian studies

What each family has been studied for

The research area, the compounds studied in it, and how far the evidence goes.

Combining families: what the evidence covers

The one combination with a pharmacological basis is a GHRH analogue with a GHRP: they act on separate receptors, and in studies giving one of each produced a larger GH response than either alone. That is a hormone measurement, not a health outcome. No trial has tested CJC-1295 with Ipamorelin, BPC-157 with TB-500, or any "longevity stack" for an effect in people. Compound Review does not publish stack or dosing protocols; outside the approved drugs named on this page, these compounds are sold for laboratory research only and are not for human or animal consumption.

Ready to Go Deeper?

Each family hub contains full compound profiles, mechanism deep-dives, the evidence and comparison guides. We do not publish dosing. Start with the family most relevant to your research focus.

Frequently Asked Questions

What are the main families of research peptides?

Research peptides are broadly categorized into six families: GHRH analogues (Sermorelin, CJC-1295, Tesamorelin), GHRP peptides (Ipamorelin, GHRP-2, GHRP-6), GLP-1 receptor agonists (Semaglutide, Tirzepatide), recovery and repair peptides (BPC-157, TB-500), longevity peptides (Epithalon, MOTS-c, SS-31), and cognitive/nootropic peptides (Selank, Semax, Dihexa). Each family acts on distinct receptor systems and serves different research applications.

What is the difference between GHRH and GHRP peptides?

GHRH analogues (like Sermorelin and CJC-1295) act on the GHRH receptor in the pituitary to stimulate GH synthesis and release. GHRP peptides (like Ipamorelin and GHRP-2) act on the ghrelin receptor (GHS-R1a) via a completely separate pathway. In studies, giving one of each produced a larger GH response than either alone; no combination has been trialled for a health outcome.

Which peptide family is best characterised?

For researchers new to peptides, GHRH analogues (particularly Sermorelin) are the most studied and best-characterized entry point. They have the longest clinical history (sermorelin was once an approved drug, and tesamorelin still is, for one use). BPC-157 has a large animal literature but almost no human data.

Can peptides from different families be combined?

Combinations are widely discussed but almost untested. GHRH with GHRP gives a larger GH response in studies; beyond that, no combination of research peptides has been trialled for an outcome in people. Compound Review does not publish stack or dosing protocols.

Are any research peptides FDA-approved?

Yes — Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy, and Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound) are FDA-approved for type 2 diabetes and obesity. The remaining peptide families (GHRP, recovery, longevity, cognitive) are not FDA-approved and are available for research purposes only.

Related Guides